These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein. Gu Z; Graci JD; Lahser FC; Breslin JJ; Jung SP; Crona JH; McMonagle P; Xia E; Liu S; Karp G; Zhu J; Huang S; Nomeir A; Weetall M; Almstead NG; Peltz SW; Tong X; Ralston R; Colacino JM Antimicrob Agents Chemother; 2013 Jul; 57(7):3250-61. PubMed ID: 23629699 [TBL] [Abstract][Full Text] [Related]
6. Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor. Mittapalli GK; Zhao F; Jackson A; Gao H; Lee H; Chow S; Kaur MP; Nguyen N; Zamboni R; McKelvy J; Wong-Staal F; Macdonald JE Bioorg Med Chem Lett; 2012 Aug; 22(15):4955-61. PubMed ID: 22784640 [TBL] [Abstract][Full Text] [Related]
7. A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide. Kang IJ; Hsu SJ; Yang HY; Yeh TK; Lee CC; Lee YC; Tian YW; Song JS; Hsu TA; Chao YS; Yueh A; Chern JH J Med Chem; 2017 Jan; 60(1):228-247. PubMed ID: 27966956 [TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase. Chen KX; Vibulbhan B; Yang W; Sannigrahi M; Velazquez F; Chan TY; Venkatraman S; Anilkumar GN; Zeng Q; Bennet F; Jiang Y; Lesburg CA; Duca J; Pinto P; Gavalas S; Huang Y; Wu W; Selyutin O; Agrawal S; Feld B; Huang HC; Li C; Cheng KC; Shih NY; Kozlowski JA; Rosenblum SB; Njoroge FG J Med Chem; 2012 Jan; 55(2):754-65. PubMed ID: 22148957 [TBL] [Abstract][Full Text] [Related]
9. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. Venkatraman S; Bogen SL; Arasappan A; Bennett F; Chen K; Jao E; Liu YT; Lovey R; Hendrata S; Huang Y; Pan W; Parekh T; Pinto P; Popov V; Pike R; Ruan S; Santhanam B; Vibulbhan B; Wu W; Yang W; Kong J; Liang X; Wong J; Liu R; Butkiewicz N; Chase R; Hart A; Agrawal S; Ingravallo P; Pichardo J; Kong R; Baroudy B; Malcolm B; Guo Z; Prongay A; Madison V; Broske L; Cui X; Cheng KC; Hsieh Y; Brisson JM; Prelusky D; Korfmacher W; White R; Bogdanowich-Knipp S; Pavlovsky A; Bradley P; Saksena AK; Ganguly A; Piwinski J; Girijavallabhan V; Njoroge FG J Med Chem; 2006 Oct; 49(20):6074-86. PubMed ID: 17004721 [TBL] [Abstract][Full Text] [Related]
10. PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally. Graci JD; Jung SP; Pichardo J; Lahser F; Tong X; Gu Z; Colacino JM Antimicrob Agents Chemother; 2016 Dec; 60(12):7060-7066. PubMed ID: 27620477 [TBL] [Abstract][Full Text] [Related]
11. Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease. Chen KX; Nair L; Vibulbhan B; Yang W; Arasappan A; Bogen SL; Venkatraman S; Bennett F; Pan W; Blackman ML; Padilla AI; Prongay A; Cheng KC; Tong X; Shih NY; Njoroge FG J Med Chem; 2009 Mar; 52(5):1370-9. PubMed ID: 19196021 [TBL] [Abstract][Full Text] [Related]
12. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies. Venkatraman S; Blackman M; Wu W; Nair L; Arasappan A; Padilla A; Bogen S; Bennett F; Chen K; Pichardo J; Tong X; Prongay A; Cheng KC; Girijavallabhan V; George Njoroge F Bioorg Med Chem; 2009 Jul; 17(13):4486-95. PubMed ID: 19481946 [TBL] [Abstract][Full Text] [Related]